BioNTech's Breakup Talks Turn Nasty as the Market Waits for Proof of Life Beyond Covid
Published on 09/26/2026 at 11:40 | Editorial boerse-global.de
BioNTech is discovering that letting go of your founders is considerably harder than making them famous. The Mainz-based group, worth EUR 21.42 billion on the market, is locked in increasingly bitter separation negotiations with U?ur ?ahin and Özlem Türeci — the husband-and-wife team whose mRNA vaccine made the company a household name — according to a Handelsblatt report published Thursday.
At issue is Arife, the new venture the pair established in Mainz on 1 September, as first reported by SWR. Arife is meant to independently develop, manufacture and market pharmaceutical products, with a sharp focus on next-generation mRNA medicines. The spin-off, however, is anything but clean. Talks are snagging on patents, specific drug candidates, financing and the movement of staff, with the planned transfer of selected mRNA rights and technologies running into serious trouble.
For shareholders, the stakes could hardly be higher. What is being haggled over in conference rooms is nothing less than the technological core on which BioNTech's future product pipeline is supposed to rest.
A Lung Cancer Readout, a Canadian Approval, and a Fresh Price Target
While the founders' exit drama plays out, the operating story has produced genuine momentum. BioNTech unveiled updated Phase 3 data for its Gotistobart candidate just over a week ago, showing extended overall survival versus standard chemotherapy in pre-treated patients with squamous non-small cell lung cancer. The shares have climbed 3.5% since.
Berenberg added its voice on 16 September, lifting its price target to USD 140 from USD 132 while keeping a Buy rating, citing the lung cancer candidate's progress. Morgan Stanley had already initiated coverage with a buy recommendation on 18 September, and another research house reaffirmed its positive stance at the start of the week.
Should investors sell immediately? Or is it worth buying BioNTech?
Regulatory news arrived as well: Health Canada granted approval on 17 September for the Pfizer and BioNTech Covid-19 vaccine adapted to the Omicron XFG variant — a reminder that the pandemic franchise still delivers dependable baseline revenue even as investors fix their gaze on oncology.
Governance Housekeeping — and a Founder Selling Down
BioNTech's supervisory board, meanwhile, is pushing ahead with formal restructuring. It approved KPMG AG WirtschaftsprĂĽfungsgesellschaft as auditor for financial year 2027, subject to election at the next annual general meeting. That shareholder gathering, where the KPMG appointment for the period ending 31 December 2027 will be put to a vote, now serves as the next formal calendar anchor.
?ahin's own share sales add a further layer of noise. Under a trading plan established on 3 June 2026 pursuant to Rule 10b5-1, the CEO offloaded another 30,000 ordinary shares on 23 September and a further 39,000 on Thursday, per SEC filings. Earlier tranches had already been disposed of mid-month. Such pre-scheduled sales are routine — but in the current climate they read as a steady, deliberate retreat.
The Question the Market Is Really Asking
Strip away the headlines and one issue dominates: can BioNTech convert late-stage oncology data into profitable approvals and commercial revenue quickly enough? Covid-19 earnings provide a balance-sheet cushion, yet they no longer suffice as a standalone share price driver. The weight has shifted entirely onto the company's own candidates in advanced trials.
Deliver statistically significant survival benefits in those studies, and access to high-margin therapeutic segments opens up. Come up short, or see regulatory milestones slip, and a re-rating looms — because the market is increasingly pricing BioNTech as an oncology researcher rather than a pandemic winner.
The upside case is not hard to sketch. Positive Phase 3 results would push filings forward in the US and Europe, partnerships or accelerated approvals could broaden the revenue base, and the Canadian vaccine nod demonstrates operational execution that funds costly trial programmes. Berenberg's raised target rests on exactly this hope: that combination therapies and targeted immunotherapies displace existing standards of care in the medium term.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Setbacks Are Part of the Deal
The flip side is concentration risk. Oncology development rarely runs smoothly — the discontinuation of the Cevumeran colorectal cancer study roughly three weeks ago is a case in point, with the stock up 1.9% since. Should further candidates miss primary endpoints, or regulators demand extra safety reviews, a meaningful chunk of hoped-for pipeline value evaporates.
Add the danger of Covid-19 booster demand eroding faster than expected. If revenue from partnerships such as the Pfizer alliance weakens unexpectedly, pressure on R&D budgets intensifies. Regulatory delays and intensifying competition from rival pharma groups chasing similar targets round out the risk list. In such a scenario, the market would have to mark down its long-term earnings expectations sharply.
The Line in the Sand
Friday's close left the stock at EUR 86.55, some distance below its 52-week high of EUR 105.80. Technically, the 200-day moving average of EUR 84.37 is the level to watch: hold above it, and confidence in the clinical pipeline and upcoming data releases prevails; slip decisively below, and scepticism about pipeline maturity and future earnings power takes over, dragging core-business risks and heavy development costs back into focus.
What the Arife dispute exposes is how narrow the path has become between honouring the pioneers who built the company and protecting shareholder value. Until it is settled which intellectual property stays in Mainz and which patents follow the founders to their new address, the pipeline carries an extra layer of uncertainty — and BioNTech must prove that its multi-billion-euro platform retains the innovative force that once defined a pandemic, even without the duo that started it all.
Ad
BioNTech Stock: New Analysis - 26 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
